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pImaging tests are ordered by clinicians to establish a
diagnosis and to provide prognostic information
that may guide the selection of therapeutic inter-
ventions. The ideal scenario for use of a diagnostic
test is one in which it replaces existing tests and its
performance is associated with the institution of
therapies that improve clinical outcomes. The evi-
dence for imaging tests is generally accumulated
over a series of steps, beginning with validation
studies comparing the test to a gold standard. These
are followed by prognostic evaluations and critically
by randomized trials assessing the impact of the
new test on clinical outcomes (1). Unfortunately,
See page 1025
very few imaging tests meet this threshold of
evidence (2). One recent example relevant to the
functional evaluation of coronary artery disease
(CAD) is that of fractional flow reserve (FFR).
Randomized trials have shown that selective use of
FFR can improve patient outcomes (3), and the test
is recommended to guide revascularization in the
presence of moderate angiographic stenoses (4).
There are several noninvasive modalities being
developed that may provide information on the
functional significance of coronary stenoses. Tech-
niques such as positron emission tomography
(PET), coronary flow reserve (CFR), and coronary
computed tomography angiography–derived FFR
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
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From the Population Health Research Institute, Hamilton Health Sci-
ences, and the Division of Cardiology, Department of Medicine, Mc-
Master University, Hamilton, Ontario, Canada. Both authors have(
reported they have no relationships relevant to the contents of this paper
to disclose.5) do not require invasive access and offer a global
valuation of the coronary circulation. The report
y Murthy et al. (6) in this issue of iJACC, is the
esult of a 5-year experience of clinical PET imag-
ng in patients with chronic kidney disease (CKD).
he investigators suggest that risk stratification
ith PET-derived global CFR may be useful in
KD patients, as both the risks of CAD events and
eriprocedural complications are increased in this
atient group. The principal finding of the study by
urthy et al. (6) is that reduced global CFR is
ommon (in about one-half of patients) in the
KD population, and that a CFR 1.5 indepen-
ently increases the risk of mortality from cardiac
auses 2-fold. This hazard ratio was higher than
raditional predictors of short-term cardiac mortal-
ty such as ejection fraction and extent of myocar-
ial ischemia/scar. (However, the event rates strat-
fied by CFR level described in Figs. 1A and 1B
ay overstate the value of global CFR as they are
ot based on simultaneous adjustment for ejection
raction and ischemia/scar.) A moderate net reclas-
ification effect is seen that is most notable in the
ntermediate risk groups.
Murthy et al. (6) are to be commended for taking
ne step toward carefully evaluating this technique.
owever, it is not far enough. Although they
uggest that knowledge of increased risk may trans-
ate into better treatment and improved outcomes,
hat has not been demonstrated and how that might
ccur is uncertain. In CKD patients, there are many
linical factors that strongly influence decision mak-
ng. In the majority of patients in the study, the
ET CFR is unlikely to influence the intensity of
edical therapy as most patients already merit
ggressive treatment. This is evident from the high
revalence of hypertension (91%), diabetes mellitus
45%), prior CAD (55%), and prior coronary revas-
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1036cularization (50%). In selecting patients for referral
to invasive angiography, clinical features are also
often important. For example, in patients with prior
revascularization (50% of patients), invasive angiog-
raphy may be indicated in symptomatic patients to
assess for restenosis or graft failure. Similarly, in
patients with recent acute coronary syndrome/
myocardial infarction (15% of patients), invasive
angiography is indicated simply because of the
unstable clinical presentation. Thus, translating an
abnormal finding on PET CFR into better patient
outcomes is a challenging endeavor. Even for well-
established CAD screening tests such as calcium
scoring and perfusion imaging, there are no data
from randomized controlled trials showing that the
use of these tests leads to improved clinical out-
comes. A recent meta-analysis demonstrated lim-
ited evidence that diagnostic testing in the preven-
tion setting impacted on patient management (7).
That may be due to inconsistent physician re-
sponses to test results or because of an insufficiently
strong association between an abnormal test resultization of the European Society of Car-
diology (ESC) and the European As-
5
6. Murthy VL, Naya M
Coronary vascularrequired for a test to be useful in screening may be
much higher than is commonly appreciated (8).
The present era is one of rapidly escalating health
care costs to which medical imaging is a big
contributor. Advocates for new and often expensive
imaging technology will need to demonstrate im-
provements in clinical outcomes, not simply improved
prognostication. Before they are widely adopted, di-
agnostic tests should be shown to make an important
difference in decision making and patient outcomes.
Indeed, it is time that the medical profession demands
such critical information and exercises restraint in
ordering imaging tests where it is lacking. This ap-
proach is needed to ensure that the limited resources
available for health care are utilized efficiently and
channeled to areas in which the most cost-effective
benefits can be expected.
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